team news

October 6, 2017

Exscientia wins best emerging biotech company award at OBN Annual Awards 2017

Exscientia, the leading Artificial Intelligence (AI)-driven drug discovery company, is pleased to announce that it was the winner of the Best Emerging Biotech Company Award at the OBN Annual Awards ceremony, celebrating outstanding achievement in the UK life sciences sector, held 5th October in Oxford, UK.

The award was presented to Andrew Hopkins, CEO of Exscientia, in recognition of the company’s outstanding success in applying AI and big data processing to accelerate drug discovery and development. This success is highlighted by the company’s collaborations with GSK, Sanofi and Evotec, representing a strong endorsement of Exscientia and validation of its approach. Through these collaborations, the company is developing single-target small molecules as well as compounds with more challenging target product profiles, through a novel bispecific small molecule strategy (compounds with dual pharmacology in an integrated pharmacophore) and phenotypic-driven drug design.

This award was judged by a panel of leading figures from the UK life sciences industry.

OBN is the membership organisation supporting and bringing together the UK’s emerging life sciences companies, corporate partners and investors.

About the OBN Annual Awards –

The OBN Awards 2017, now in their 9th year, celebrate innovation and outstanding achievement across the UK Life Sciences industry. Categories are broad ranging and include Biotech, Medtech, Synthetic Biology, Digital Healthcare and Investment.  This year they also launched a new category, Best CRO which looks to recognise the critical support services provided by Contract Research Organisations across the pharmaceutical, biotech and medtech industries.

Liked the article? Let’s share it!